Since the FDA approved the first antibody-drug conjugate for treating Acute Myeloid Leukemia (AML) in 2000, it paved the way for a world of possibilities for drug development. Traditionally developed for cancer treatment, applications such as autoimmune, neurological, cardiovascular, and infectious diseases are actively explored. Drug conjugates are varied, from antibodies conjugated to small molecules or oligos to small molecule-targeting ligands conjugated with cytotoxic drugs. The development of each type of conjugate comes with unique challenges. KreaMedica’s team of experts can help you design a preclinical program and navigate the challenges inherent to your compound to satisfy regulatory requirements.
I have had the pleasure of working with KreaMedica on several programs. They proactively identified and addressed issues and provided regular updates to ensure everyone was on the same page. Their attention to detail and willingness to take ownership of the project’s success makes them invaluable partners. They are great to work with, and I would highly recommend them to anyone looking for a drug development partner.
They supplemented and filled in gaps in our internal network and worked well with our advisors. They truly wanted to contribute to and be part of the project’s success. I highly recommend Claude, Poulomee, and Rudi as reliable partners for planning and executing toxicological and bioanalytical projects.
I have worked with KreaMedica for many years, and I must credit them for the team’s talent, professionalism, and chemistry. That doesn’t happen by accident. As a consultant, I rely on them as the first line to monitor studies and provide proactive solutions when required.